Pressure BioSciences (PBIO) 10-Q 20 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38185
Entity Registrant Name	PRESSURE BIOSCIENCES, INC.
Entity Central Index Key	0000830656
Entity Tax Identification Number	04-2652826
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	14 Norfolk Avenue
Entity Address, City or Town	South Easton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02375
City Area Code	(508)
Local Phone Number	230-1828
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,726,433

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 5,263	$ 3,865
Accounts receivable	329,263	295,374
Inventories, net of $905,759 and $982,973 reserve, respectively	467,155	686,383
Prepaid expenses and other current assets	219,283	257,527
Total current assets	1,020,964	1,243,149
Investment in equity securities	77,918	63,638
Property and equipment, net	91,409	103,351
Right of use asset operating leases	159,424	282,095
Intangible assets, net	252,404	317,308
TOTAL ASSETS	1,602,119	2,009,541
CURRENT LIABILITIES
Accounts payable	1,062,565	637,238
Accrued employee compensation	376,760	167,247
Accrued professional fees and other	2,722,666	2,497,762
Accrued interest and dividends payable	4,576,350	10,803,983
Deferred revenue	253,152	58,242
Convertible debt, net of unamortized debt discounts of $744,393 and $455,517, respectively	18,222,120	17,823,669
Other debt, net of unamortized discounts of $0 and $0, respectively	2,030,510	1,638,969
Related party, net of unamortized debt discount of $514 and $7,915, respectively	647,986	634,885
Right of use operating lease liability	66,259	142,171
Total current liabilities	29,958,368	34,404,166
LONG TERM LIABILITIES
Long term debt	162,522	150,000
Right of use operating lease liability long term	71,287	139,924
Deferred revenue	10,645	1,822
TOTAL LONG TERM LIABILITIES	244,454	291,746
TOTAL LIABILITIES	30,202,822	34,695,912
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS’ DEFICIT
Preferred stock, value	100	1,098
Common stock, $.01 par value; 100,000,000 shares authorized; 23,399,945 and 13,682,910 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively	234,000	136,829
Warrants to acquire common stock	35,684,321	31,995,762
Additional paid-in capital	93,973,646	69,006,145
Accumulated deficit	(158,492,770)	(133,826,205)
TOTAL STOCKHOLDERS’ DEFICIT	(28,600,703)	(32,686,371)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,602,119	$ 2,009,541

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Inventory valuation reserves	$ 905,759	$ 982,973
Debt instrument, unamortized discount	744,393	455,517
Other debt, unamortized discounts net.	$ 0	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, share,issued	23,399,945	13,682,910
Common stock, shares, outstanding	23,399,945	13,682,910
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series H Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series H2 Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series J Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series K Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series AA Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series BB Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series CC Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Convertible Debt [Member]
Debt instrument, unamortized discount	$ 744,393	$ 455,517
Related Party [Member]
Debt instrument, unamortized discount	$ 514	$ 7,915

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Products, services, other	$ 413,009	$ 144,032	$ 1,665,412	$ 1,122,169
Total revenue	413,009	144,032	1,665,412	1,122,169
Costs and expenses:
Cost of products and services	229,457	126,203	844,684	742,707
Research and development	288,345	262,370	1,004,437	716,685
Selling and marketing	157,773	226,526	537,802	422,422
General and administrative	1,030,243	892,293	5,290,564	2,591,644
Total operating costs	1,705,818	1,507,392	7,677,487	4,473,458
Operating loss	(1,292,809)	(1,363,360)	(6,012,075)	(3,351,289)
Other (expense) income:
Interest expense, net	(4,338,759)	(2,034,021)	(14,112,098)	(6,448,771)
Unrealized gain (loss) on investment in equity securities	(5,965)	(8,675)	14,280	(8,047)
Gain (loss) on extinguishment of liabilities		(1,054,122)	687,591	(1,809,249)
Other income (expense)	7,588	(2,059)	11,820	(904)
Total other expense	(4,337,136)	(3,098,877)	(13,398,407)	(8,266,971)
Net loss	(5,629,945)	(4,462,237)	(19,410,482)	(11,618,260)
Deemed dividends on extension of warrants			(3,626,950)
Preferred stock dividends	(632,054)	(431,709)	(1,629,133)	(1,295,566)
Net loss attributable to common shareholders	$ (6,261,999)	$ (4,893,946)	$ (24,666,565)	$ (12,913,826)
Basic net loss per share attributable to common shareholders	$ (0.29)	$ (0.44)	$ (1.21)	$ (1.24)
Diluted net loss per share attributable to common shareholders	$ (0.29)	$ (0.44)	$ (1.21)	$ (1.24)
Weighted average number of shares of common stock outstanding, basic	21,716,950	11,131,742	20,337,229	10,429,817
Weighted average number of shares of common stock outstanding, diluted	21,716,950	11,131,742	20,337,229	10,429,817

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parenthetical)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Product and Service, Other [Member]	Product and Service, Other [Member]	Product and Service, Other [Member]	Product and Service, Other [Member]

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,410,482)	$ (11,618,260)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) on extinguishment of debt	(687,591)	(10,000)
Non-cash lease expense	122,671	82,001
Common stock and warrants issued for interest	3,715,204	2,196,278
Depreciation and amortization	84,341	67,985
Accretion of interest and amortization of debt discount	3,213,622	1,777,863
Loss on extinguishment of accrued liabilities and debt		1,809,249
Common stock and warrants issued for debt extension	1,671,573
Preferred stock issued for debt extension	2,683,600
Stock-based compensation expense	1,706,420	128,984
(Gain)/Loss on investment in equity securities	(14,280)	8,047
Common stock and warrants issued for services	1,978,645	367,370
Preferred stock issued for services	617,200
Changes in operating assets and liabilities:
Accounts receivable	(33,889)	(11,568)
Inventories	219,228	(238,973)
Prepaid expenses and other assets	38,244	204,141
Accounts payable	425,327	80,130
Accrued employee compensation	209,513	104,258
Operating lease liability	(144,549)	(82,001)
Deferred revenue and other accrued expenses	1,551,380	2,083,239
Net cash used in operating activities	(2,053,823)	(3,051,257)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(7,495)	(20,754)
Net cash used in investing activities	(7,495)	(20,754)
CASH FLOWS FROM FINANCING ACTIVITIES:
Sale of common stock for cash	150,000
Proceeds from stock option exercises	81,111	17,443
Net proceeds from convertible debt	4,336,665	3,428,249
Net proceeds from non-convertible debt - third party	2,043,681	1,815,000
Net proceeds from debt - related party	159,186	762,500
Payments on convertible debt	(2,462,269)	(1,086,946)
Payments on debt - related party	(159,000)	(259,600)
Payments on non-convertible debt	(2,086,658)	(1,506,066)
Net cash provided by financing activities	2,062,716	3,170,580
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,398	98,569
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	3,865	132,311
CASH AND CASH EQUIVALENTS AT END OF PERIOD	5,263	230,880
CASH FLOWS SUPPLEMENTAL INFORMATION
Interest paid in cash	1,219,038	938,451
NON CASH TRANSACTIONS:
Early adoption of ASU 2020-06		473,027
Common stock issued with debt	1,293,270	512,593
Discount from warrants issued with debt		93,576
Common stock issued in lieu of cash for dividend	162,528	306,333
Preferred stock issued with debt	539,487
Preferred stock dividends	1,629,133	1,295,566
Conversion of preferred stock for common stock	14,869	44
Conversion of debt, interest, preferred stock dividend for preferred stock	10,017,212
Conversion of debt and interest into common stock	509,033	350,500
Conversion of common stock for preferred stock	6,240
Extension of warrants for Series AA preferred stock	$ 3,626,950

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1,099	$ 91,206	$ 31,715,154	$ 64,261,048	$ (118,277,468)	$ (22,208,961)
Balance, shares at Dec. 31, 2021	109,878	9,120,526
Stock-based compensation				64,483		64,483
Series AA Preferred Stock dividend					(432,149)	(432,149)
Issuance of common stock for services		$ 370		77,330		77,700
Issuance of common stock for services, shares		37,000
Stock warrants issued			39,761			39,761
Conversion of debt and interest for common stock		$ 1,402		349,098		350,500
Conversion of debt and interest for common stock, shares		140,200
Issuance of common stock for dividends paid-in-kind		$ 318		63,938		64,256
Issuance of common stock for dividends paid-in-kind, shares		31,810
Issuance of common stock for interest paid-in-kind		$ 5,581		1,167,877		1,173,458
Issuance of common stock for interest paid-in-kind, shares		558,100
Common stock issued for debt extension		$ 2,145		470,755		472,900
Common stock issued for debt extension, shares		214,500
Stock issued with debt		$ 920		141,560		142,480
Stock issued with debt, shares		92,000
Net loss					(4,239,685)	(4,239,685)
Early adoption of ASU 2020-06				(2,728,243)	2,255,216	(473,027)
Warrants issued for debt extension			132,537			132,537
Warrants issued with debt			87,436			87,436
Balance at Mar. 31, 2022	$ 1,099	$ 101,942	31,974,888	63,867,846	(120,694,086)	(24,748,311)
Balance, shares at Mar. 31, 2022	109,878	10,194,136
Beginning balance, value at Dec. 31, 2021	$ 1,099	$ 91,206	31,715,154	64,261,048	(118,277,468)	(22,208,961)
Balance, shares at Dec. 31, 2021	109,878	9,120,526
Net loss						(11,618,260)
Extension of warrants for Series AA Preferred stock
Balance at Sep. 30, 2022	$ 1,098	$ 122,207	31,995,762	67,041,489	(128,936,078)	(29,775,522)
Balance, shares at Sep. 30, 2022	109,874	12,220,611
Beginning balance, value at Mar. 31, 2022	$ 1,099	$ 101,942	31,974,888	63,867,846	(120,694,086)	(24,748,311)
Balance, shares at Mar. 31, 2022	109,878	10,194,136
Stock option exercise		$ 253		17,190		17,443
Stock option exercise, shares		25,279
Stock-based compensation				32,074		32,074
Series AA Preferred Stock dividend					(431,708)	(431,708)
Issuance of common stock for services		$ 400		67,400		67,800
Issuance of common stock for services, shares		40,000
Issuance of common stock for dividends paid-in-kind		$ 865		150,156		151,021
Issuance of common stock for dividends paid-in-kind, shares		86,464
Issuance of common stock for interest paid-in-kind		$ 2,245		386,270		388,515
Issuance of common stock for interest paid-in-kind, shares		224,500
Common stock issued for debt extension		$ 1,064		190,239		191,303
Common stock issued for debt extension, shares		106,400
Stock issued with debt		$ 220		35,628		35,848
Stock issued with debt, shares		22,000
Conversion of preferred stock for common stock	$ (1)	$ 44		(43)
Conversion of preferred stock for common stock, shares	(4)	4,400
Net loss					(2,916,338)	(2,916,338)
Balance at Jun. 30, 2022	$ 1,098	$ 107,033	31,974,888	64,746,760	(124,042,132)	(27,212,353)
Balance, shares at Jun. 30, 2022	109,874	10,703,179
Stock-based compensation				32,427		32,427
Series AA Preferred Stock dividend					(431,709)	(431,709)
Issuance of common stock for services		$ 1,135		166,240		167,375
Issuance of common stock for services, shares		113,500
Stock warrants issued			6,140			6,140
Issuance of common stock for dividends paid-in-kind		$ 520		90,536		91,056
Issuance of common stock for dividends paid-in-kind, shares		52,032
Issuance of common stock for interest paid-in-kind		$ 3,895		630,410		634,305
Issuance of common stock for interest paid-in-kind, shares		389,500
Common stock issued for debt extension		$ 7,079		1,043,396		1,050,475
Common stock issued for debt extension, shares		707,900
Stock issued with debt		$ 2,545		331,720		334,265
Stock issued with debt, shares		254,500
Net loss					(4,462,237)	(4,462,237)
Warrants issued for services			14,734			14,734
Balance at Sep. 30, 2022	$ 1,098	$ 122,207	31,995,762	67,041,489	(128,936,078)	(29,775,522)
Balance, shares at Sep. 30, 2022	109,874	12,220,611
Beginning balance, value at Dec. 31, 2022	$ 1,098	$ 136,829	31,995,762	69,006,145	(133,826,205)	(32,686,371)
Balance, shares at Dec. 31, 2022	109,874	13,682,910
Stock option exercise		$ 1,176		79,935		81,111
Stock option exercise, shares		117,552
Stock-based compensation				1,430,244		1,430,244
Series AA Preferred Stock dividend					(431,807)	(431,807)
Issuance of common stock for services		$ 9,905		1,409,430		1,419,335
Issuance of common stock for services, shares		990,500
Stock warrants issued			61,609			61,609
Conversion of debt and interest for common stock		$ 2,036		506,997		509,033
Conversion of debt and interest for common stock, shares		203,613
Issuance of common stock for dividends paid-in-kind		$ 737		101,698		102,435
Issuance of common stock for dividends paid-in-kind, shares		73,694
Issuance of common stock for interest paid-in-kind		$ 11,111		1,694,123		1,705,234
Issuance of common stock for interest paid-in-kind, shares		1,111,081
Common stock issued for debt extension		$ 5,682		1,024,257		1,029,939
Common stock issued for debt extension, shares		568,200
Stock issued with debt		$ 7,832		1,079,919		1,087,751
Stock issued with debt, shares		783,150
Conversion of preferred stock for common stock	$ (1,012)	$ 4,935		(3,923)
Conversion of preferred stock for common stock, shares	(101,154)	493,540
Sale of Common Stock		$ 400		99,600		100,000
Stock issued with debt, shares		40,000
Net loss					(6,857,834)	(6,857,834)
Balance at Mar. 31, 2023	$ 86	$ 180,643	32,057,371	76,428,425	(141,115,846)	(32,449,321)
Balance, shares at Mar. 31, 2023	8,720	18,064,240
Beginning balance, value at Dec. 31, 2022	$ 1,098	$ 136,829	$ 31,995,762	69,006,145	(133,826,205)	$ (32,686,371)
Balance, shares at Dec. 31, 2022	109,874	13,682,910
Stock option exercise, shares						117,552
Net loss						$ (19,410,482)
Extension of warrants for Series AA Preferred stock						3,626,950
Balance at Sep. 30, 2023	$ 100	$ 234,000	$ 35,684,321	93,973,646	(158,492,770)	(28,600,703)
Balance, shares at Sep. 30, 2023	9,935	23,399,945
Beginning balance, value at Mar. 31, 2023	$ 86	$ 180,643	32,057,371	76,428,425	(141,115,846)	(32,449,321)
Balance, shares at Mar. 31, 2023	8,720	18,064,240
Stock-based compensation				135,554		135,554
Series AA Preferred Stock dividend					(565,272)	(565,272)
Issuance of common stock for services		$ 1,475		170,925		172,400
Issuance of common stock for services, shares		147,500
Conversion of debt and interest for common stock	$ 4			10,017,208		10,017,212
Conversion of debt and interest for common stock, shares	401
Issuance of common stock for dividends paid-in-kind		$ 690		59,403		60,093
Issuance of common stock for dividends paid-in-kind, shares		69,073
Issuance of common stock for interest paid-in-kind		$ 10,340		1,286,106		1,296,446
Issuance of common stock for interest paid-in-kind, shares		1,034,000
Common stock issued for debt extension		$ 5,286		486,348		491,634
Common stock issued for debt extension, shares		528,600
Stock issued with debt		$ 3,021		153,653		156,674
Stock issued with debt, shares		302,092
Conversion of preferred stock for common stock		$ 444		(444)
Conversion of preferred stock for common stock, shares	(44)	44,400
Sale of Common Stock		$ 200		49,800		50,000
Stock issued with debt, shares		20,000
Net loss					(6,922,703)	(6,922,703)
Extension of warrants for Series AA Preferred stock			3,626,950		(3,626,950)
Conversion of common stock to preferred stock	$ 1	$ (6,240)		6,239
Conversion of common stock to preferred stock, shares	62	(624,000)
Issuance of preferred stock for services	$ 1			505,699		505,700
Issuance of preferred stock for services, shares	57
Issuance of Preferred stock for debt extension	$ 2			1,396,998		1,397,000
Preferred stock for debt extension	185
Preferred stock issued with debt	$ 1			539,486		539,487
Preferred stock issued for debt, share	58
Balance at Jun. 30, 2023	$ 95	$ 195,859	35,684,321	91,235,400	(152,230,771)	(25,115,096)
Balance, shares at Jun. 30, 2023	9,439	19,585,905
Stock-based compensation				140,622		140,622
Series AA Preferred Stock dividend					(632,054)	(632,054)
Issuance of common stock for services		$ 4,926		320,375		325,301
Issuance of common stock for services, shares		492,500
Issuance of common stock for interest paid-in-kind		$ 19,490		694,034		713,524
Issuance of common stock for interest paid-in-kind, shares		1,949,040
Common stock issued for debt extension		$ 2,500		147,500		150,000
Common stock issued for debt extension, shares		250,000
Stock issued with debt		$ 1,735		47,110		48,845
Stock issued with debt, shares		173,500
Conversion of preferred stock for common stock	$ (1)	$ 9,490		(9,489)
Conversion of preferred stock for common stock, shares	(95)	949,000
Net loss					(5,629,945)	(5,629,945)
Issuance of preferred stock for services				111,500		111,500
Issuance of preferred stock for services, shares	35
Issuance of Preferred stock for debt extension	$ 6			1,286,594		1,286,600
Preferred stock for debt extension	556
Balance at Sep. 30, 2023	$ 100	$ 234,000	$ 35,684,321	$ 93,973,646	$ (158,492,770)	$ (28,600,703)
Balance, shares at Sep. 30, 2023	9,935	23,399,945

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure BioSciences, Inc. (OTCQB: PBIO The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion-dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform. The UST Platform 3. The Company began shipping Nano CBD topical spray on October 2, 2023. The BaroFold Platform The PCT Platform

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows from operationing business since our inception. As of September 30, 2023, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past as described in Notes 5 and 6. In addition, we raised debt and equity capital after September 30, 2023, as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3) Summary of Significant Accounting Policies Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023. Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended Nine Months Ended Primary geographical markets 2023 2022 2023 2022 North America $ 251 $ 138 $ 1,067 $ 709 Europe 76 13 130 61 Asia 86 (7 ) 468 352 $ 413 $ 144 $ 1,665 $ 1,122 Three Months Ended Nine Months Ended Major products/services lines 2023 2022 2023 2022 Hardware $ 273 $ 1 $ 994 $ 532 Consumables 50 49 173 165 Contract research services -1 - 35 125 Sample preparation accessories 31 41 113 93 Technical support/extended service contracts 34 41 123 94 Agrochem Products 15 10 181 93 Shipping and handling 11 2 38 20 Other - - 8 - $ 413 $ 144 $ 1,665 $ 1,122 Three Months Ended Nine Months Ended Timing of revenue recognition 2023 2022 2023 2022 Products transferred at a point in time $ 379 $ 103 $ 1,506 $ 903 Services transferred over time 34 41 159 219 $ 413 $ 144 $ 1,665 $ 1,122 Contract balances Schedule of Contract Balances In thousands of US dollars ($) September 30, 2023 December 31, 2022 Receivables, which are included in ‘Accounts Receivable’ $ 329 $ 295 Contract liabilities (deferred revenue) 59 60 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2023 2024 Total Extended warranty service $ 48 $ 11 $ 59 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022. Schedule of Customer Concentration Risk Percentage Three Months Ended Nine months Ended 2023 2022 2023 2022 Top five customers 80 % 42 % 49 % 31 % Federal agencies 18 % 4 % 5 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable. September 30, December 31, Top five customers 80 % 93 % Federal agencies 22 % 0 % Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments. Investment in Equity Securities As of September 30, 2023, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 77,918 14,280 Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022: Schedule of Computation of Loss Per Share 2023 2022 2023 2022 For the Three Months Ended September 30, For the Nine months Ended September 30, 2023 2022 2023 2022 Numerator: Net loss attributable to common shareholders $ (6,261,999 ) $ (4,893,946 ) $ (24,666,565 ) $ (12,913,826 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 21,716,950 11,131,742 20,337,229 10,429,817 Loss per common share - basic and diluted $ (0.29 ) $ (0.44 ) $ (1.21 ) $ (1.24 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share As of September 30, 2023 2022 Stock options 3,420,754 1,307,822 Convertible debt 7,417,906 6,471,034 Common stock warrants 15,732,940 16,293,768 Convertible preferred stock: Series D Convertible Preferred Stock 6,250 25,000 Series G Convertible Preferred Stock - 26,857 Series H Convertible Preferred Stock - 33,334 Series H2 Convertible Preferred Stock - 70,000 Series J Convertible Preferred Stock - 115,267 Series K Convertible Preferred Stock - 229,334 Series AA Convertible Preferred Stock 8,601,000 8,645,000 Series BB Convertible Preferred Stock 8,580,000 - Series CC Convertible Preferred Stock 4,010,000 - 47,768,850 33,217,416 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023: Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Officers and Employees Expected life 6.0 Expected volatility 130.5 % Risk-free interest rate 3.90 % Forfeiture rate 0 5.00 % Expected dividend yield 0.0 % Valuation and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 0 5 All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance. The Company recognized stock-based compensation expense of $ 140,622 32,427 1,706,420 128,984 Schedule of Stock Based Compensation Expense For the Three Months Ended For the Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Cost of sales $ 11,183 $ 2,184 $ 75,724 $ 8,694 Research and development 35,676 9,499 241,585 37,803 Selling and marketing 17,150 4,583 102,675 18,166 General and administrative 76,613 16,161 1,286,436 64,321 Total stock-based compensation expense $ 140,622 $ 32,427 $ 1,706,420 $ 128,984 Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at September 30, 2023 using: September 30, 2023 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 77,918 $ 77,918 - - Total Financial Assets $ 77,918 $ 77,918 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022: Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 63,638 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $ 7,650 December 31, 2023 We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease required monthly payments of $ 7,282 The lease shall be automatically extended for additional three years unless either party terminates at least nine months prior to the expiration of the current lease term The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $ 221,432 12 On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $ 239,327 12 Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2023: Schedule of Future Minimum Rental Payments Required Under Operating Leases Year Total October 1 – December 31, 2023 $ 15,887 2024 64,393 2025 66,969 2026 51,778 Total future undiscounted lease payments 199,027 Less imputed interest (61,481 ) Present value of lease liabilities $ 137,546 The operating cash flows from the operating leases were $ 122,671 82,001 2.59 Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets: Schedule of Right of Use Asset and the Corresponding Lease Liability Operating Leases September 30, 2023 December 31, 2022 Right of use asset $ 159,424 $ 282,095 Right of use liability, current $ 66,259 $ 142,171 Right of use liability, long term $ 71,287 $ 139,924 Total lease liability $ 137,546 $ 282,095 The weighted-average discount rate is 12 The Company had no financing leases during the nine months ended September 30, 2023 and 2022. The components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows: Schedule of Lease Cost for Operating Leases September 30, 2023 September 30, 2022 Operating lease cost $ 153,290 $ 152,193 Short-term lease cost 110,205 123,514 Total lease cost $ 263,495 $ 275,707 Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle 1,200 2,000 3,000 4,000 5,000 Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $ 1,400 2,000 60,000 60,000 55,400 65,100 Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by the Company without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the occurrence of a change in control, as a disincentive to the control change.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	5) Debt Convertible Debt On various dates during the nine months ended September 30, 2023, the Company issued convertible notes for net proceeds of approximate total of $ 4.3 1 12 0 120 2.50 1,832,757 For the nine months ended September 30, 2023, deferred financing costs and OID issued with the debt are $ 648,470 2,462,269 The summary of specific terms of the convertible notes and outstanding balances as of September 30, 2023, and December 31, 2022, are listed in the tables below. The convertible notes are from numerous parties and with original issue dates from July 2019 to September 2023 and maturity dates from July 2020 to September 2024 12.3 Schedule of Convertible Debts and Outstanding Balances September 30, 2023 December 31, 2022 Holders Interest Conversion Principal Interest Conversion Principal Main Investor 10 % $ 2.50 $ 8,586,750 10 % $ 2.50 ) $ 9,393,150 Others 0 24 % $ 2.50 7.50 10,379,763 0 24 % $ 2.50 7.50 8,886,036 Totals - 18,279,186 Discount 744,393 455,517 Net $ 18,222,120 $ 17,823,669 Notes: (1) Conversion price of these note is $ 2.50 189,750 25 729,100 2.50 (2) Conversion price of these notes is $ 2.50 a. Notes are convertible before maturity at $ 2.50 2.50 b. Notes are convertible upon an Event of Default at 75 c. Notes are convertible at $ 2.50 75 d. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 30 e. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 25 f. Conversion price is lower of (i) $ 2.50 g. Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50 70 h. Conversion price is $ 2.50 1 i. Notes can be voluntarily converted before maturity at $ 2.50 2.50 10 j. Notes can be converted at the lesser of $ 2.5 25 35 k. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $ 950,000 l. Some notes can be converted at the lesser of $ 2.50 25 5 For the nine months ended September 30, 2023, the Company recognized amortization expense related to the debt discounts indicated above of $ 2,621,523 744,393 As of September 30, 2023, the principal balance that is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $ 352,188 Standstill and Forbearance Agreements In recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. During the nine months ended September 30, 2023, the Company settled one note with total principal of $ 302,484 272,500 253,425 Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the nine months ended September 30, 2023 at substantially the same terms for extensions ranging over a period of two to nine months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10 0.7 3,917,898 4,067,898 1,346,800 741 Other Debt No notes in Other Debt are past due as of September 30, 2023. Schedule of Other Debt September 30, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Non-Convertible - ) $ 1,016,500 - ) $ 878,809 Merchant debt (3) 1,014,010 760,160 SBA (2) 3.75 % 162,522 3.75 % 150,000 Totals 2,193,032 $ 1,788,969 Discount - - Long Term 162,522 150,000 Short Term $ 2,030,510 $ 1,638,969 Notes: (1) Interest varies from 1 10 May 2, 2023 861,500 (2) The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 14,719 2,197 367,039 1 367,039 (3) During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 100.9 maturity dates ranged from June 26, 2023 to October 15, 2023 maturity dates ranged from April 4 to June 6, 2023 Related Party Notes Schedule of Related Party Debt September 30, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Security Officers & Directors - ) $ 522,450 - ) $ 521,950 Unsecured Other Related Parties 12 % 126,050 12 % 120,850 Unsecured Totals 648,500 642,800 Discount 514 7,915 Net $ 647,986 $ 634,885 Notes: (1) Interest varies from 12 120 During the nine months ended September 30, 2023, we received short-term convertible loans of $ 164,700 5,514 159,000 12 120 2.50 We amortized $ 592,099 of debt discounts during the nine months ended September 30, 2023 for all non-convertible and related party notes. The total unamortized discount for all non-convertible and related party convertible notes as of September 30, 2023, and December 31, 2022 was $ 514 and $ 7,915 , respectively.

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Deficit	6) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 0.01 1,000,000 Schedule of Preferred Stock Outstanding September 30, 2023 December 31, 2022 Series D Convertible Preferred Stock, $ .01 850 75 300 300,000 $ - $ 3 Series G Convertible Preferred Stock, $ .01 240,000 80,570 - 806 Series H Convertible Preferred Stock, $ .01 10,000 no 10,000 - 100 Series J Convertible Preferred Stock, $ .01 6,250 no 3,458 - 35 Series K Convertible Preferred Stock, $ .01 15,000 no 6,880 - 68 Series AA Convertible Preferred Stock, $ .01 10,000 8,601 86 86 Series BB Convertible Preferred Stock, $ .01 1,000 858 no 10 - Series CC Convertible Preferred Stock, $ .01 2,000 401 no 4 - Series H2 Convertible Preferred Stock, $ .01 21 no 21 - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 100 $ 1,098 On May 1, 2023, Pressure Biosciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization (the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 0.01 2,000 0.01 Series BB Preferred Stock Rank 0.01 Dividends Voting Rights The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held Voluntary Conversion 10,000 Company Forced Conversion 300 2.50 Series CC Preferred Stock Rank Quarterly Dividends 8 Junior Stock Dividends Class Voting Rights 10 75 50 General Voting Rights Liquidation Preference 25,000.00 Voluntary Conversion 2.50 Company Forced Conversion 300 10 Conversion Restriction 4.99 During the nine months ended September 30, 2023 the Company issued a total of 953 401 ● 92 617,200 ● 741 2,683,600 ● 58 539,487 ● 62 ● 95 ● 401 10,017,212 Stock Options and Warrants At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 3,420,754 As of September 30, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $ 963,322 2.2 0.20 0.00 The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Average Weighted Average Total Shares price per share Shares price per share Shares Exercisable Balance outstanding, December 31, 2022 1,307,822 $ 0.72 16,278,769 $ 3.50 17,586,591 17,570,591 Granted 2,230,484 1.50 100,000 3.50 2,330,484 Exercised (117,552 ) 0.69 - - (117,552 ) Expired - - (645,829 ) 3.50 (645,829 ) Forfeited - - - - - Balance outstanding, September 30, 2023 3,420,754 $ 1.23 15,732,940 $ 3.50 19,153,694 18,289,721 As of September 30, 2023, the 3,420,754 1.23 8.14 7.75 2,556,781 On April 13, 2023, the Board authorized a 3-year extension of common stock warrants held by Series AA preferred shares holders. Therefore, 8,897,603 3,626,950 As of September 30, 2023, the warrants outstanding have a $ 3.50 2.42 Common Stock and Warrant Issuances During the nine months ended September 30, 2023, the Company accrued approximately $ 3,715,204 634,305 During the nine months ended September 30, 2023 the Company issued a total of 9,717,035 ● 4,094,121 3,715,204 ● 1,630,500 1,917,036 203,613 509,033 117,552 0.69 142,767 162,528 1,258,742 1,293,270 1,346,800 1,671,573 60,000 150,000 ● 1,486,940 During the nine months ended September 30, 2023, the Company issued 100,000 3.50 61,609 During the nine months ended September 30, 2022, we issued 3,100,085 shares of restricted common stock to accredited investors and consultants, 140,200 shares with a fair value of $ 350,500 for conversions of debt principal and interest for common stock, 1,172,100 of the shares with a fair value of $ 2,196,278 were issued for interest paid-in-kind, 190,500 of the shares with a fair value of $ 312,875 were issued for services rendered, 170,306 shares with a fair value of $ 306,333 for dividends paid-in-kind, 368,500 shares with a fair value $ 512,593 for new convertible debt issuances, 25,279 shares with a fair value of $ 17,433 from a stock option exercise, 1,028,800 shares with a fair value of $ 1,714,678 for debt extension and shareholders converted shares of series AA convertible preferred stock into 4,400 shares of common stock During the nine months ended September 30, 2022, we issued 277,500 3.50 280,608

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	7) Subsequent Events From October 1, 2023, through November 10, 2023, the Company issued seven (7) convertible loan with a principal balance of $ 439,000 . The terms of the convertible notes were 15 days to 12 months with interest rates of 10 - 120 % and convertible into the Company’s common stock at a fixed rate of $ 2.50 per share. In this time the Company also issued 278,500 shares of common stock for new convertible debt loans in the third quarter, 455,350 shares of common stock for accrued interest paid-in-kind, 310,000 shares of common stock for debt extensions, 505,000 shares of common stock from the conversion of Series BB preferred stock, 145,809 shares of common stock for Series AA preferred dividends and 40 Series BB preferred stock for professional services. On October 18, 2023, the Board of Directors (the “Board”) of Pressure BioSciences, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Pressure BioSciences, Inc. 2021 Equity Incentive Plan (the “Plan”). The Plan originally provided that no one person could be granted awards pursuant to the Plan during any one fiscal year to purchase more than 300,000 0.01 500,000 On the same date, the Board granted a total of 1,500,000 0.25 25 25 3 In addition, on the same date, the Board approved the repricing of all outstanding options (including those held by the Board members and the named executive officers) to $ 0.25 0.69 1.50 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. Such statements include, without limitation, statements regarding: ● our need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all; ● our need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient additional financing; ● our belief that we will have sufficient liquidity to finance normal operations for the foreseeable future; ● the options we may pursue in light of our financial condition; ● the potential applications for Ultra Shear Technology ( UST ● the potential applications of the BaroFold high-pressure protein refolding and disaggregation technology ● the amount of cash necessary to operate our business; ● the anticipated uses of grant revenue and the potential for increased grant revenue in future periods; ● our plans and expectations with respect to our continued operations; ● the expected number of Pressure Cycling Technology (“PCT”) and Constant Pressure (“CP”) based units that we believe will be installed and the expected revenues from the sale of consumable products, extended service contracts, and biopharma contract services; ● our belief that PCT has achieved initial market acceptance in the mass spectrometry and other markets; ● the expected development and success of new instrument and consumables product offerings; ● the potential applications for our instrument and consumables product offerings; ● the expected expenses of, and benefits and results from, our research and development efforts; ● the expected benefits and results from our collaboration programs, strategic alliances and joint ventures; ● our expectations of the results of our development activities funded by government research grants; ● the potential size of the market for biological sample preparation, biopharma contract services and Ultra Shear Technology; ● general economic conditions; ● the anticipated future financial performance and business operations of our company; ● our reasons for resources expended in the market for genomic, proteomic, lipidomic and small molecule sample preparation; ● the importance of mass spectrometry as a laboratory tool; ● the advantages of PCT over other current technologies as a method of biological sample preparation and protein characterization in biomarker discovery, forensics, and histology, as well as for other applications; ● the capabilities and benefits of our PCT Sample Preparation System, consumables and other products; ● our belief that laboratory scientists will achieve results comparable with those reported to date by certain research scientists who have published or presented publicly on PCT and our other products and services; ● our ability to retain our core group of scientific, administrative and sales personnel; and ● our ability to expand our customer base in sample preparation and for other applications of PCT, as well as for our other products and services in both the BaroFold and Ultra Shear Technology areas. These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 and in this Report. We qualify all of our forward-looking statements by these cautionary statements. Pressure BioSciences, Inc. (OTCQB: PBIO The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform. The UST Platform The BaroFold Platform The PCT Platform 2023 Key Accomplishments From January 1, 2023 to September 30, 2023, we announced the following key accomplishments: ● September 22: ● September 21: ● September 8: ● August 30: ● August 22: ● August 9: . ● July 26: ● July 25: ● July 17: ● July 10: ● July 6: ● July 5: ● June 13: ● June 1: ● May 22: ● May 16: ● May 9: ● April 26: ● April 21, 2023: ● April 18: ● April 14: ● April 6, 2023: ● March 28: ● March 22: ● March 1: ● February 1: ● January 27: ● January 19: Results of Operations The following disclosure compares the results of operations for the quarter ended September 30, 2023 (“Q2 2023”) with September 30, 2022 (“Q2 2022”) and compares the nine months ended September 30, 2023 with September 30, 2022. Products and Services Revenue We recognized total revenue of $413,009 for Q3 2023 compared to $144,032 for Q3 2022, a 187% increase. For the year-to-date periods ending September 30, 2023 and September 30, 2022, we recognized revenue of $1,665,412 and $1,122,169 respectively, a 48% increase. This increase in revenue was primarily attributable to a $506,828 increase in PCT instrumentation and consumable sales, a $30,295 increase in technical support services and an $87,378 increase in Agrochem products, offset by a decrease of $89,350 in scientific services. Cost of Products and Services The cost of products and services was $229,457 for Q3 2023 compared to $126,203 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022 our cost of products and services were $844,684 and $742,707, respectively. Gross profit margin on products and services increased to 49% in the year-to-date period ended September 30, 2023 from 34% in the same period ended September 30, 2022. The increase in gross profit margin was attributable to $180,670 of Agrochem products sold in 2023 at no cost due to 2022 inventory write-off and a $79,901 instrument non-monetary exchange sale in 2022 was recorded at no profit. Research and Development Research and development expenses were $288,345 for Q3 2023 compared to $262,370 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $1,004,437 and $716,685, respectively, a 40% increase. The reported increase was due to a $71,777 reclass of salaries to COGS for a non-monetary instrument exchange in 2022 and $241,585 of stock-based compensation expense for employee stock options issued in 2023. Selling and Marketing Selling and marketing expenses were $157,773 for Q3 2023 compared to $226,526 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $537,802 and $422,422, respectively a 27% increase The reported increase was primarily attributable to the hiring of a Marketing FTE in Q2 2023 and $102,675 of stock-based compensation expense for employee stock options issued in 2023. General and Administrative General and administrative expenses were $1,030,244 for Q3 2023 compared to $892,293 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $5,290,564 and $2,591,644, respectively, a 104% increase. The increase was primarily due to approximately $2.0 million common stock and warrants issued for services, approximately $1.3 million of stock-based compensation expense for employee, BOD and financial consultant stock options issued in 2023, and approximately $132,000 of financial consulting expenses in 2023, offset by an approximately $423,000 decrease in IR expenses. Operating Loss Operating loss was $1,292,809 for Q3 2023 compared to $1,363,360 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, the operating loss was $6,012,075 and $3,551,289 respectively, a 79% increase. This increase was primarily due to $2.0 millions in common stock and warrants issued for services and $1.7 million of stock-based compensation expense for employee, BOD financial consultant stock options issued in 2023, offset by an approximate $423,000 decrease in IR expenses. Interest Expense, net Interest expense was $4,338,759 for Q3 2023 compared to $2,034,021 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $14,112,098 and $6,448,771, respectively, a 119% increase. This increase was attributable to an increase in convertible debt and merchant cash loans, in addition to stock issuances for interest paid in kind and stock issued for debt extensions. Unrealized gain on investment in equity securities Unrealized loss on investments in equity securities was $5,965 for Q3 2023 compared to an unrealized loss of $8,675 for Q3 2022. For the nine months ended September 30, 2023, the unrealized gain on investment in equity securities was $14,280 as compared to an unrealized loss of $8,047 for the nine months ended September 30, 2022. The reported change was attributable to movement in the market price of the Company’s investment in Nexity. Loss on extinguishment of liabilities In connection with debt extensions and forgiveness, we recognized a net gain of $0 for Q3 2023 compared to $1,054,122 of losses for Q3 2022. For the nine months ended September 30, 2023 the recognized net gain of $687,591 as compared to a net loss of $1,809,249 for the nine months ended September 30, 2022. The increase/decline in gains/losses was attributable to decreased extension and forgiveness activity. Net loss attributable to common stockholders Net loss attributable to common stockholders was $6,261,999 ($0.29 per share) for Q3 2023 compared to $4,893,946 ($0.44 per share) for Q3 2022. For the nine months ended September 30, 2023, the net loss attributable to common stock was $24,666,565 ($1.21 per share) as compared to $12,913,826 ($1.24 per share). Liquidity and Financial Condition We have experienced negative cash flows from operations since our inception. As of September 30, 2023, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have substantial doubt regarding our ability to continue as a going concern. As described in Notes 5 and 6 of the accompanying consolidated financial statements, we have been successful in raising debt and equity capital. We received approximately $6.5 million in net proceeds from loans in the nine months ended September 30, 2023. We have efforts in place to continue to raise cash through debt and equity offerings. (See Note 7 to the financial statements) We will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects. Net cash used in operations for the nine months ended September 30, 2023 was $2,053,823 as compared to $3,051,257 for the nine months ended September 30, 2022. Net cash used in investing activities for the nine months ended September 30, 2023 was $7,495 compared to $20,754 in the nine months ended September 30, 2022. Net cash provided by financing activities for the nine months ended September 30, 2023 was $2,062,716 as compared to $3,170,580 for the nine months ended September 30, 2022. This Item 3 is not applicable to us as a smaller reporting company and has been omitted. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 filings are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective. Our conclusion that our disclosure controls and procedures were not effective as of September 30, 2023 is due to the continued presence of the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended December 31, 2022. These material weaknesses are the following: ● We identified a lack of sufficient segregation of duties. Specifically, this material weakness is such that the design over these areas relies primarily on detective controls and could be strengthened by adding preventative controls to properly safeguard Company assets. ● Management has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training, and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles, particularly as it relates to valuation of warrants and other complex debt /equity transactions. Specifically, this material weakness resulted in audit adjustments to the annual consolidated financial statements and revisions to related disclosures, valuation of warrants and other equity transactions. ● Limited policies and procedures that cover recording and reporting of financial transactions. ● Lack of multiple levels of review over the financial reporting process We continue to plan to remediate those material weaknesses as follows: ● Improve the effectiveness of the accounting group by augmenting our existing resources with additional consultants or employees to assist in the analysis and recording of complex accounting transactions, and to simultaneously achieve desired organizational structuring for improved segregation of duties. We plan to mitigate this identified deficiency by hiring an independent consultant once we generate significantly more revenue or raise significant additional working capital. ● Improve expert review and achieve desired segregation procedures by strengthening cross approval of various functions including quarterly internal audit procedures where appropriate once we generate significantly more revenue or raise significantly more working capital. During the period covered by this Report, we implemented and performed additional substantive procedures, such as supervisory review of work papers and consistent use of financial models used in equity valuations, to ensure our consolidated financial statements as of and for the six-month period ended September 30, 2023, are fairly stated in all material respects in accordance with GAAP. We have not, however, been able to fully remediate the material weaknesses due to our limited financial resources. Our remediation efforts are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner. Except as described above, there have been no changes in our internal controls over financial reporting that occurred during the period ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2022 and, in this Item, 1A. The risks described in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks occur, our business, results of operations, cash flows or financial condition could suffer. There have been no material changes to the risk factors set forth in Item 1A of our 10-K for the year ended December 31, 2022. Except where noted, all the securities discussed in this Part II, Item 2 were issued in reliance on the exemption under Section 4(a)(2) of the Securities Act. On various dates in the nine months ended September 30, 2023 the Company issued a total of 9,917,035 of its common shares, 953 shares of Series BB preferred stock and 401 shares of Series CC preferred stock as follows: ● 117,552 shares from option exercises; ● 1,630,500 shares for professional services; ● 1,346,800 shares for debt extensions; ● 203,613 shares for conversion of debt and interest; ● 142,767 shares for dividends paid-in-kind; ● 4,094,121 shares for interest paid-in-kind; ● 1,258,742 shares for shares issued with debt; ● 60,000 shares from sale of common shares; ● 95 shares of Series BB preferred stock was converted to common stock; ● 92 shares of Series BB preferred stock for professional services; ● 741 shares of Series BB preferred stock for debt extensions; ● 58 shares of Series BB preferred stock issued with debt; ● 401 shares of Series CC preferred stock for conversion of debt/accrued interest and dividends, and ● 62 shares of Series BB preferred stock for the conversion of common stock. None. Not applicable. None. Exhibits 21.1* Securities Issuance and Exchange Agreement 31.1* Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)) 31.2* Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)) 32.1** Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* 32.2** Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* 101.INS* Inline XBRL Instance Document 101.SCH* Inline XBRL Taxonomy Extension Schema Document 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are furnished and not filed. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PRESSURE BIOSCIENCES, INC. Date: November 20, 2023 By: /s/ Richard T. Schumacher Richard T. Schumacher President & Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended Nine Months Ended Primary geographical markets 2023 2022 2023 2022 North America $ 251 $ 138 $ 1,067 $ 709 Europe 76 13 130 61 Asia 86 (7 ) 468 352 $ 413 $ 144 $ 1,665 $ 1,122 Three Months Ended Nine Months Ended Major products/services lines 2023 2022 2023 2022 Hardware $ 273 $ 1 $ 994 $ 532 Consumables 50 49 173 165 Contract research services -1 - 35 125 Sample preparation accessories 31 41 113 93 Technical support/extended service contracts 34 41 123 94 Agrochem Products 15 10 181 93 Shipping and handling 11 2 38 20 Other - - 8 - $ 413 $ 144 $ 1,665 $ 1,122 Three Months Ended Nine Months Ended Timing of revenue recognition 2023 2022 2023 2022 Products transferred at a point in time $ 379 $ 103 $ 1,506 $ 903 Services transferred over time 34 41 159 219 $ 413 $ 144 $ 1,665 $ 1,122 Contract balances Schedule of Contract Balances In thousands of US dollars ($) September 30, 2023 December 31, 2022 Receivables, which are included in ‘Accounts Receivable’ $ 329 $ 295 Contract liabilities (deferred revenue) 59 60 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2023 2024 Total Extended warranty service $ 48 $ 11 $ 59 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022. Schedule of Customer Concentration Risk Percentage Three Months Ended Nine months Ended 2023 2022 2023 2022 Top five customers 80 % 42 % 49 % 31 % Federal agencies 18 % 4 % 5 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable. September 30, December 31, Top five customers 80 % 93 % Federal agencies 22 % 0 %
Product Supply	Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.
Investment in Equity Securities	Investment in Equity Securities As of September 30, 2023, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 77,918 14,280
Computation of Loss per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022: Schedule of Computation of Loss Per Share 2023 2022 2023 2022 For the Three Months Ended September 30, For the Nine months Ended September 30, 2023 2022 2023 2022 Numerator: Net loss attributable to common shareholders $ (6,261,999 ) $ (4,893,946 ) $ (24,666,565 ) $ (12,913,826 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 21,716,950 11,131,742 20,337,229 10,429,817 Loss per common share - basic and diluted $ (0.29 ) $ (0.44 ) $ (1.21 ) $ (1.24 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share As of September 30, 2023 2022 Stock options 3,420,754 1,307,822 Convertible debt 7,417,906 6,471,034 Common stock warrants 15,732,940 16,293,768 Convertible preferred stock: Series D Convertible Preferred Stock 6,250 25,000 Series G Convertible Preferred Stock - 26,857 Series H Convertible Preferred Stock - 33,334 Series H2 Convertible Preferred Stock - 70,000 Series J Convertible Preferred Stock - 115,267 Series K Convertible Preferred Stock - 229,334 Series AA Convertible Preferred Stock 8,601,000 8,645,000 Series BB Convertible Preferred Stock 8,580,000 - Series CC Convertible Preferred Stock 4,010,000 - 47,768,850 33,217,416
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023: Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Officers and Employees Expected life 6.0 Expected volatility 130.5 % Risk-free interest rate 3.90 % Forfeiture rate 0 5.00 % Expected dividend yield 0.0 % Valuation and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 0 5 All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance. The Company recognized stock-based compensation expense of $ 140,622 32,427 1,706,420 128,984 Schedule of Stock Based Compensation Expense For the Three Months Ended For the Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Cost of sales $ 11,183 $ 2,184 $ 75,724 $ 8,694 Research and development 35,676 9,499 241,585 37,803 Selling and marketing 17,150 4,583 102,675 18,166 General and administrative 76,613 16,161 1,286,436 64,321 Total stock-based compensation expense $ 140,622 $ 32,427 $ 1,706,420 $ 128,984 Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at September 30, 2023 using: September 30, 2023 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 77,918 $ 77,918 - - Total Financial Assets $ 77,918 $ 77,918 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022: Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 63,638 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue In thousands of US dollars ($) Three Months Ended Nine Months Ended Primary geographical markets 2023 2022 2023 2022 North America $ 251 $ 138 $ 1,067 $ 709 Europe 76 13 130 61 Asia 86 (7 ) 468 352 $ 413 $ 144 $ 1,665 $ 1,122 Three Months Ended Nine Months Ended Major products/services lines 2023 2022 2023 2022 Hardware $ 273 $ 1 $ 994 $ 532 Consumables 50 49 173 165 Contract research services -1 - 35 125 Sample preparation accessories 31 41 113 93 Technical support/extended service contracts 34 41 123 94 Agrochem Products 15 10 181 93 Shipping and handling 11 2 38 20 Other - - 8 - $ 413 $ 144 $ 1,665 $ 1,122 Three Months Ended Nine Months Ended Timing of revenue recognition 2023 2022 2023 2022 Products transferred at a point in time $ 379 $ 103 $ 1,506 $ 903 Services transferred over time 34 41 159 219 $ 413 $ 144 $ 1,665 $ 1,122
Schedule of Contract Balances	Contract balances Schedule of Contract Balances In thousands of US dollars ($) September 30, 2023 December 31, 2022 Receivables, which are included in ‘Accounts Receivable’ $ 329 $ 295 Contract liabilities (deferred revenue) 59 60
Schedule of Future Related to Performance Obligations	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2023 2024 Total Extended warranty service $ 48 $ 11 $ 59
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022. Schedule of Customer Concentration Risk Percentage Three Months Ended Nine months Ended 2023 2022 2023 2022 Top five customers 80 % 42 % 49 % 31 % Federal agencies 18 % 4 % 5 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable. September 30, December 31, Top five customers 80 % 93 % Federal agencies 22 % 0 %
Schedule of Computation of Loss Per Share	The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022: Schedule of Computation of Loss Per Share 2023 2022 2023 2022 For the Three Months Ended September 30, For the Nine months Ended September 30, 2023 2022 2023 2022 Numerator: Net loss attributable to common shareholders $ (6,261,999 ) $ (4,893,946 ) $ (24,666,565 ) $ (12,913,826 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 21,716,950 11,131,742 20,337,229 10,429,817 Loss per common share - basic and diluted $ (0.29 ) $ (0.44 ) $ (1.21 ) $ (1.24 )
Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share As of September 30, 2023 2022 Stock options 3,420,754 1,307,822 Convertible debt 7,417,906 6,471,034 Common stock warrants 15,732,940 16,293,768 Convertible preferred stock: Series D Convertible Preferred Stock 6,250 25,000 Series G Convertible Preferred Stock - 26,857 Series H Convertible Preferred Stock - 33,334 Series H2 Convertible Preferred Stock - 70,000 Series J Convertible Preferred Stock - 115,267 Series K Convertible Preferred Stock - 229,334 Series AA Convertible Preferred Stock 8,601,000 8,645,000 Series BB Convertible Preferred Stock 8,580,000 - Series CC Convertible Preferred Stock 4,010,000 - 47,768,850 33,217,416
Summary of Assumptions for Grants of Stock Options	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023: Summary of Assumptions for Grants of Stock Options Assumptions CEO, other Officers and Employees Expected life 6.0 Expected volatility 130.5 % Risk-free interest rate 3.90 % Forfeiture rate 0 5.00 % Expected dividend yield 0.0 %
Schedule of Stock Based Compensation Expense	Schedule of Stock Based Compensation Expense For the Three Months Ended For the Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Cost of sales $ 11,183 $ 2,184 $ 75,724 $ 8,694 Research and development 35,676 9,499 241,585 37,803 Selling and marketing 17,150 4,583 102,675 18,166 General and administrative 76,613 16,161 1,286,436 64,321 Total stock-based compensation expense $ 140,622 $ 32,427 $ 1,706,420 $ 128,984
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at September 30, 2023 using: September 30, 2023 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 77,918 $ 77,918 - - Total Financial Assets $ 77,918 $ 77,918 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022: Fair value measurements at December 31, 2022 using: December 31, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 63,638 63,638 - - Total Financial Assets $ 63,638 $ 63,638 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2023: Schedule of Future Minimum Rental Payments Required Under Operating Leases Year Total October 1 – December 31, 2023 $ 15,887 2024 64,393 2025 66,969 2026 51,778 Total future undiscounted lease payments 199,027 Less imputed interest (61,481 ) Present value of lease liabilities $ 137,546
Schedule of Right of Use Asset and the Corresponding Lease Liability	Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets: Schedule of Right of Use Asset and the Corresponding Lease Liability Operating Leases September 30, 2023 December 31, 2022 Right of use asset $ 159,424 $ 282,095 Right of use liability, current $ 66,259 $ 142,171 Right of use liability, long term $ 71,287 $ 139,924 Total lease liability $ 137,546 $ 282,095
Schedule of Lease Cost for Operating Leases	The components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows: Schedule of Lease Cost for Operating Leases September 30, 2023 September 30, 2022 Operating lease cost $ 153,290 $ 152,193 Short-term lease cost 110,205 123,514 Total lease cost $ 263,495 $ 275,707

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	Schedule of Convertible Debts and Outstanding Balances September 30, 2023 December 31, 2022 Holders Interest Conversion Principal Interest Conversion Principal Main Investor 10 % $ 2.50 $ 8,586,750 10 % $ 2.50 ) $ 9,393,150 Others 0 24 % $ 2.50 7.50 10,379,763 0 24 % $ 2.50 7.50 8,886,036 Totals - 18,279,186 Discount 744,393 455,517 Net $ 18,222,120 $ 17,823,669 Notes: (1) Conversion price of these note is $ 2.50 189,750 25 729,100 2.50 (2) Conversion price of these notes is $ 2.50 a. Notes are convertible before maturity at $ 2.50 2.50 b. Notes are convertible upon an Event of Default at 75 c. Notes are convertible at $ 2.50 75 d. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 30 e. Notes can be voluntary converted at lower of 1) $ 2.50 2.50 2.50 25 f. Conversion price is lower of (i) $ 2.50 g. Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50 70 h. Conversion price is $ 2.50 1 i. Notes can be voluntarily converted before maturity at $ 2.50 2.50 10 j. Notes can be converted at the lesser of $ 2.5 25 35 k. Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $ 950,000 l. Some notes can be converted at the lesser of $ 2.50 25 5
Schedule of Other Debt	Schedule of Other Debt September 30, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Non-Convertible - ) $ 1,016,500 - ) $ 878,809 Merchant debt (3) 1,014,010 760,160 SBA (2) 3.75 % 162,522 3.75 % 150,000 Totals 2,193,032 $ 1,788,969 Discount - - Long Term 162,522 150,000 Short Term $ 2,030,510 $ 1,638,969 Notes: (1) Interest varies from 1 10 May 2, 2023 861,500 (2) The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 14,719 2,197 367,039 1 367,039 (3) During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1 100.9 maturity dates ranged from June 26, 2023 to October 15, 2023 maturity dates ranged from April 4 to June 6, 2023
Schedule of Related Party Debt	Schedule of Related Party Debt September 30, 2023 December 31, 2022 Holders Interest Rate Principal Interest Rate Principal Security Officers & Directors - ) $ 522,450 - ) $ 521,950 Unsecured Other Related Parties 12 % 126,050 12 % 120,850 Unsecured Totals 648,500 642,800 Discount 514 7,915 Net $ 647,986 $ 634,885 Notes: (1) Interest varies from 12 120

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Preferred Stock Outstanding	Schedule of Preferred Stock Outstanding September 30, 2023 December 31, 2022 Series D Convertible Preferred Stock, $ .01 850 75 300 300,000 $ - $ 3 Series G Convertible Preferred Stock, $ .01 240,000 80,570 - 806 Series H Convertible Preferred Stock, $ .01 10,000 no 10,000 - 100 Series J Convertible Preferred Stock, $ .01 6,250 no 3,458 - 35 Series K Convertible Preferred Stock, $ .01 15,000 no 6,880 - 68 Series AA Convertible Preferred Stock, $ .01 10,000 8,601 86 86 Series BB Convertible Preferred Stock, $ .01 1,000 858 no 10 - Series CC Convertible Preferred Stock, $ .01 2,000 401 no 4 - Series H2 Convertible Preferred Stock, $ .01 21 no 21 - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 100 $ 1,098
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Average Weighted Average Total Shares price per share Shares price per share Shares Exercisable Balance outstanding, December 31, 2022 1,307,822 $ 0.72 16,278,769 $ 3.50 17,586,591 17,570,591 Granted 2,230,484 1.50 100,000 3.50 2,330,484 Exercised (117,552 ) 0.69 - - (117,552 ) Expired - - (645,829 ) 3.50 (645,829 ) Forfeited - - - - - Balance outstanding, September 30, 2023 3,420,754 $ 1.23 15,732,940 $ 3.50 19,153,694 18,289,721

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Product Information [Line Items]
Revenue	$ 413,009	$ 144,032	$ 1,665,412	$ 1,122,169
Hardware [Member]
Product Information [Line Items]
Revenue	273,000	1,000	994,000	532,000
Consumables [Member]
Product Information [Line Items]
Revenue	50,000	49,000	173,000	165,000
Contract Research Services [Member]
Product Information [Line Items]
Revenue	(1,000)		35,000	125,000
Sample Preparation Accessories [Member]
Product Information [Line Items]
Revenue	31,000	41,000	113,000	93,000
Technical Support/Extended Service Contracts [Member]
Product Information [Line Items]
Revenue	34,000	41,000	123,000	94,000
Agrochem Products [Member]
Product Information [Line Items]
Revenue	15,000	10,000	181,000	93,000
Shipping and Handling [Member]
Product Information [Line Items]
Revenue	11,000	2,000	38,000	20,000
Other [Member]
Product Information [Line Items]
Revenue			8,000
Transferred at a Point In Time [Member]
Product Information [Line Items]
Revenue	379,000	103,000	1,506,000	903,000
Transferred Over At Time [Member]
Product Information [Line Items]
Revenue	34,000	41,000	159,000	219,000
North America [Member]
Product Information [Line Items]
Revenue	251,000	138,000	1,067,000	709,000
Europe [Member]
Product Information [Line Items]
Revenue	76,000	13,000	130,000	61,000
Asia [Member]
Product Information [Line Items]
Revenue	$ 86,000	$ (7,000)	$ 468,000	$ 352,000

Schedule of Contract Balances (

Schedule of Contract Balances (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Receivables, which are included in ‘Accounts Receivable’	$ 329	$ 295
Contract liabilities (deferred revenue)	$ 59	$ 60

Schedule of Future Related to P

Schedule of Future Related to Performance Obligations (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 59
2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	48
2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 11

Schedule of Customer Concentrat

Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Top Five Customers [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	80%	42%	49%	31%
Top Five Customers [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage			80%		93%
Federal Agencies [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	18%	4%	5%	1%
Federal Agencies [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage			22%		0%

Schedule of Computation of Loss

Schedule of Computation of Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accounting Policies [Abstract]
Net loss attributable to common shareholders	$ (6,261,999)	$ (4,893,946)	$ (24,666,565)	$ (12,913,826)
Weighted average common stock shares outstanding basic	21,716,950	11,131,742	20,337,229	10,429,817
Weighted average common stock shares outstanding diluted	21,716,950	11,131,742	20,337,229	10,429,817
Loss per common share - basic	$ (0.29)	$ (0.44)	$ (1.21)	$ (1.24)
Loss per common share - diluted	$ (0.29)	$ (0.44)	$ (1.21)	$ (1.24)

Schedule of Anti-Dilutive Secur

Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	47,768,850	33,217,416
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,420,754	1,307,822
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	7,417,906	6,471,034
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	15,732,940	16,293,768
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	6,250	25,000
Series G Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		26,857
Series H Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		33,334
Series H2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		70,000
Series J Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		115,267
Series K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		229,334
Series AA Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,601,000	8,645,000
Series BB Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,580,000
Series CC Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	4,010,000

Summary of Assumptions for Gran

Summary of Assumptions for Grants of Stock Options (Details) - CEO, other Officers and Employees [Member]	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Line Items]
Expected life	6 years
Expected volatility	130.50%
Risk-free interest rate	3.90%
Expected dividend yield	0%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Forfeiture rate	0%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Forfeiture rate	5%

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total stock-based compensation expense	$ 140,622	$ 32,427	$ 1,706,420	$ 128,984
Cost of Sales [Member]
Total stock-based compensation expense	11,183	2,184	75,724	8,694
Research and Development Expense [Member]
Total stock-based compensation expense	35,676	9,499	241,585	37,803
Selling and Marketing Expense [Member]
Total stock-based compensation expense	17,150	4,583	102,675	18,166
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 76,613	$ 16,161	$ 1,286,436	$ 64,321

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Financing Receivable, Past Due [Line Items]
Total Financial Assets	$ 77,918	$ 63,638
Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	77,918	63,638
Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	77,918	63,638
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	77,918	63,638
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 30, 2020
Property, Plant and Equipment [Line Items]
Cumulative effect of adoption, adjustment in additional paid in capital	$ 93,973,646		$ 93,973,646		$ 69,006,145	$ 2,728,243
Cumulative effect of adoption, adjustment in accumulated deficit	(158,492,770)		(158,492,770)		$ (133,826,205)	$ 2,255,216
Stock-based compensation expense	$ 140,622	$ 32,427	$ 1,706,420	$ 128,984
Minimum [Member]
Property, Plant and Equipment [Line Items]
Forfeiture rate	0%		0%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Forfeiture rate	5%		5%
Nexity Global SA [Member]
Property, Plant and Equipment [Line Items]
Sale of stock number of shares received			100,250
Investment owned, at fair value	$ 77,918		$ 77,918
Unrealized gain			$ 14,280

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
October 1 – December 31, 2023	$ 15,887
2024	64,393
2025	66,969
2026	51,778
Total future undiscounted lease payments	199,027
Less imputed interest	(61,481)
Present value of lease liabilities	$ 137,546	$ 282,095

Schedule of Right of Use Asset

Schedule of Right of Use Asset and the Corresponding Lease Liability (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Right of use asset	$ 159,424	$ 282,095
Right of use liability, current	66,259	142,171
Right of use liability, long term	71,287	139,924
Total lease liability	$ 137,546	$ 282,095

Schedule of Lease Cost for Oper

Schedule of Lease Cost for Operating Leases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 153,290	$ 152,193
Short-term lease cost	110,205	123,514
Total lease cost	$ 263,495	$ 275,707

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Aug. 09, 2021

Apr. 30, 2012

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2022

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]

Operating lease liability

$ 137,546

$ 137,546

$ 282,095

Operating lease

$ 122,671

$ 82,001

Weighted-average remaining lease term

2 years 7 months 2 days

2 years 7 months 2 days

Weighted-average discount rate

12%

12%

Expenses

$ 1,705,818

$ 1,507,392

$ 7,677,487

4,473,458

Battelle Memorial Institute [Member]

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]

Mimimum royalty fee

$ 5,000

$ 4,000

$ 3,000

$ 2,000

$ 1,200

Target Discovery Inc [Member]

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]

Mimimum royalty fee

60,000

60,000

Payments for fees

$ 1,400

Professional and contract services expense

$ 2,000

Expenses

55,400

$ 65,100

Medford lease [Member]

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]

Annual cost of living payment

$ 7,282

Lessee operating lease description

The lease shall be automatically extended for additional three years unless either party terminates at least nine months prior to the expiration of the current lease term

Operating lease liability

$ 221,432

$ 221,432

Estimated borrowing rate

12%

12%

Sparks lease [Member]

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]

Lessee operating lease description

On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term

Operating lease liability

$ 239,327

$ 239,327

Estimated borrowing rate

12%

12%

Corporate Office [Member]

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]

Lease monthly payments

$ 7,650

Lease expiration date

Dec. 31, 2023

Schedule of Convertible Debts a

Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Conversion price		$ 2.50
Totals			$ 18,279,186
Debt unamortized discount		744,393	455,517
Principal amount		$ 18,222,120	$ 17,823,669
Investor [Member]
Debt Instrument [Line Items]
Interest Rate		10%	10%
Conversion price	[1]	$ 2.50	$ 2.50
Totals		$ 8,586,750	$ 9,393,150
Others [Member]
Debt Instrument [Line Items]
Totals		$ 10,379,763	$ 8,886,036
Others [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest Rate		0%	0%
Conversion price	[2]	$ 2.50	$ 2.50
Others [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest Rate		24%	24%
Conversion price		$ 7.50	$ 7.50
[1]Conversion price of these note is $ 2.50 189,750 25 729,100 2.50 2.50

Schedule of Convertible Debts_2

Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)	9 Months Ended
	Sep. 30, 2023 USD ($) Integer $ / shares
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Debt default amount | $	$ 1
Debt instrument, convertible, conversion price	$ 2.50
Debt default convertible conversion ratio	75%
Debt instrument, convertible, conversion price, Increase	$ 2.50
Debt instrument, convertible, conversion price, decrease	$ 2.50
Percentage of price	10%
Convertible lesser per share	$ 2.5
Convertible lesser Percent	25%
Original debt, interest rate of debt	35%
Principal balance | $	$ 12,300,000
Trading day | Integer	5
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Principal balance | $	$ 950,000
Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Debt default amount | $	$ 189,750
Debt instrument lowest trading price	25%
Convertible Debt [Member] | Series AA Preferred Stock [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Convertible Debt [Member] | 5 Day Average VWAP [Member]
Short-Term Debt [Line Items]
Debt default amount | $	$ 729,100
Convertible Debt One [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible price per shares	$ 2.50
Convertible Debt Two [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	30%
Convertible Debt Three [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	25%
Convertible Debt Four [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	70%

Schedule of Other Debt (Details

Schedule of Other Debt (Details) - USD ($)		Sep. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Totals, Principal		$ 2,193,032	$ 1,788,969
Long Term, discount
Long Term, Principal		162,522	150,000
Short Term, Principal		$ 2,030,510	$ 1,638,969
Non Convertible [Member]
Short-Term Debt [Line Items]
Interest Rate	[1]
Totals, Principal		$ 1,016,500	$ 878,809
Merchant Debt [Member]
Short-Term Debt [Line Items]
Totals, Principal	[2]	$ 1,014,010	$ 760,160
SBA [Member]
Short-Term Debt [Line Items]
Interest Rate	[3]	3.75%	3.75%
Totals, Principal	[3]	$ 162,522	$ 150,000
[1]Interest varies from 1 10 May 2, 2023 861,500 4.1 100.9 maturity dates ranged from June 26, 2023 to October 15, 2023 maturity dates ranged from April 4 to June 6, 2023 150,000 3.75 731 14,719 2,197 367,039 1 367,039

Schedule of Other Debt (Detai_2

Schedule of Other Debt (Details) (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt instrument, maturity date	May 02, 2023
Non- convertible debt amount	$ 861,500
Note payable	$ 150,000
Accrued interest rate percent	3.75%
Debt Instrument periodic payment	$ 731
Deferred interest	14,719
Principal amount paid	$ 2,197
Debt instrument, maturity date description	July 2020 to September 2024
Merchant Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date description	maturity dates ranged from June 26, 2023 to October 15, 2023	maturity dates ranged from April 4 to June 6, 2023
Payroll Protection Program [Member]
Debt Instrument [Line Items]
Borrowed amount				$ 367,039
Debt interest rate				1%
Paycheck Protection Programme [Member]
Debt Instrument [Line Items]
Borrowed amount			$ 367,039
Minimum [Member]
Debt Instrument [Line Items]
Debt interest rate	1%
Minimum [Member] | Merchant Agreement [Member]
Debt Instrument [Line Items]
Debt interest rate	4.10%
Maximum [Member]
Debt Instrument [Line Items]
Debt interest rate	10%
Maximum [Member] | Merchant Agreement [Member]
Debt Instrument [Line Items]
Debt interest rate	100.90%

Schedule of Related Party Debt

Schedule of Related Party Debt (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Totals, Principle		$ 731
Net, Principal		$ 647,986	$ 634,885
Officers & Directors [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest Rate	[1]
Totals, Principle		$ 522,450	$ 521,950
Other Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest Rate		12%	12%
Totals, Principle		$ 126,050	$ 120,850
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Totals, Principle		648,500	642,800
Discount, Principal		514	7,915
Net, Principal		$ 647,986	$ 634,885
[1]Interest varies from 12 120

Schedule of Related Party Deb_2

Schedule of Related Party Debt (Details) (Parenthetical)	Sep. 30, 2023
Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	1%
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	10%
Related Party [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	12%
Related Party [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	120%

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Short-Term Debt [Line Items]
Proceeds from Convertible Debt							$ 4,336,665	$ 3,428,249
Fixed rate	$ 2.50						$ 2.50
Deferred Costs	$ 648,470						$ 648,470
Repayments of Senior Debt							$ 2,462,269
Debt instrument maturity date description							July 2020 to September 2024
Debt instrument, face amount.	12,300,000						$ 12,300,000
Debt Instrument, Unamortized Discount	744,393						744,393		$ 455,517
Payments on convertible debt							2,462,269	1,086,946
Losses on extinguishment of debt							$ 687,591	$ 10,000
Preferred stock extensions	1,286,600	$ 1,397,000
Debt instrument, convertible price per shares							$ 2.50
Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt Instrument, Unamortized Discount	$ 744,393						$ 744,393		455,517
Debt instrument, convertible price per shares							$ 2.50
Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued	250,000	528,600	568,200	707,900	106,400	214,500
Preferred stock extensions
Preferred Stock [Member]
Short-Term Debt [Line Items]
Preferred stock extensions	6	$ 2
Three Lenders [Member]
Short-Term Debt [Line Items]
Payments on convertible debt							$ 302,484
Three Lenders [Member] | Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Payments on convertible debt							272,500
Four Lenders [Member] | Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Interest payable	253,425						253,425
PBI Agrochem Inc [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount.	$ 352,188						$ 352,188
Minimum [Member]
Short-Term Debt [Line Items]
Debt interest rate	1%						1%
Maximum [Member]
Short-Term Debt [Line Items]
Debt interest rate	10%						10%
Convertible Debt [Member]
Short-Term Debt [Line Items]
Proceeds from Convertible Debt							$ 4,300,000
Amortization of Debt Discount (Premium)							2,621,523
Debt Instrument, Unamortized Discount	$ 744,393						$ 744,393
Convertible Debt [Member] | Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Fixed rate	$ 2.50						$ 2.50
Convertible Debt, Fair Value Disclosures	$ 1,832,757						$ 1,832,757
Convertible Debt [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument term							1 month
Debt interest rate	0%						0%
Convertible Debt [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument term							12 months
Debt interest rate	120%						120%
New Loan [Member]
Short-Term Debt [Line Items]
Debt interest rate	10%						10%
Losses on extinguishment of debt							$ 700,000
Ten Loans [Member]
Short-Term Debt [Line Items]
Proceeds from loans							3,917,898
Increase in principal amount							$ 4,067,898
Ten Loans [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued							1,346,800
Ten Loans [Member] | Preferred Stock [Member]
Short-Term Debt [Line Items]
Preferred stock extensions							$ 741
Short-term Non-Convertible Loan [Member]
Short-Term Debt [Line Items]
Amortization of Debt Discount (Premium)							592,099
Debt Instrument, Unamortized Discount	$ 514						514		$ 7,915
Proceeds from Short-Term Debt							164,700
Original issue discount							5,514
Proceeds from (Repayments of) Related Party Debt							$ 159,000
Short-term Non-Convertible Loan [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt interest rate	12%						12%
Short-term Non-Convertible Loan [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt interest rate	120%						120%

Schedule of Preferred Stock Out

Schedule of Preferred Stock Outstanding (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 100	$ 1,098
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding	100	1,098
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 3
Preferred stock, shares outstanding	75	300
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 806
Preferred stock, shares outstanding	80,570	80,570
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 100
Preferred stock, shares outstanding	0	10,000
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 35
Preferred stock, shares outstanding	0	3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares		$ 68
Preferred stock, shares outstanding	0	6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 86	$ 86
Preferred stock, shares outstanding	8,601	8,601
Series BB Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 10
Preferred stock, shares outstanding	858	0
Series CC Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 4
Preferred stock, shares outstanding	401	0
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	21
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding
Preferred stock, shares outstanding	0	0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0

Schedule Of Preferred Stock O_2

Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) - USD ($)	Sep. 30, 2023	May 01, 2023	Dec. 31, 2022
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	850		850
Preferred stock, shares issued	75		300
Preferred stock, shares outstanding	75		300
Preferred stock, shares outstanding			$ 300,000
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	10,000		10,000
Preferred stock, shares issued	0		10,000
Preferred stock, shares outstanding	0		10,000
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	240,000		240,000
Preferred stock, shares issued	80,570		80,570
Preferred stock, shares outstanding	80,570		80,570
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	6,250		6,250
Preferred stock, shares issued	0		3,458
Preferred stock, shares outstanding	0		3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	15,000		15,000
Preferred stock, shares issued	0		6,880
Preferred stock, shares outstanding	0		6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	10,000		10,000
Preferred stock, shares issued	8,601		8,601
Preferred stock, shares outstanding	8,601		8,601
Series BB Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000	1,000	1,000
Preferred stock, shares issued	858
Preferred stock, shares outstanding	858		0
Series CC Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000	2,000	2,000
Preferred stock, shares issued	401
Preferred stock, shares outstanding	401		0
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	21		21
Preferred stock, shares issued	0		21
Preferred stock, shares outstanding	0		21
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	20,000		20,000
Preferred stock, shares outstanding	0		0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	313,960		313,960
Preferred stock, shares outstanding	0		0
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized			279,256
Preferred stock, shares outstanding	0		0
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	88,098		88,098
Preferred stock, shares outstanding	0		0
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01		$ 0.01
Preferred stock, shares authorized	500		500
Preferred stock, shares outstanding	0		0

Schedule of Concerning Options

Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	17,586,591
Exercisable, Beginning balance	17,570,591
Shares, Granted	2,330,484
Shares, Exercised	(117,552)
Shares, Expired	(645,829)
Shares, Forfeited
Shares, Ending balance	19,153,694
Exercisable, Ending balance	18,289,721
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	1,307,822
Weighted average price per share, Beginning balance | $ / shares	$ 0.72
Shares, Granted	2,230,484
Weighted average price per share, Granted | $ / shares	$ 1.50
Shares, Exercised	(117,552)
Weighted average price per share, Exercised | $ / shares	$ 0.69
Shares, Expired
Weighted average price per share, Expired | $ / shares
Shares, Forfeited
Weighted average price per share, Forfeited | $ / shares
Shares, Ending balance	3,420,754
Weighted average price per share, Ending balance | $ / shares	$ 1.23
Exercisable, Ending balance	2,556,781
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning balance	16,278,769
Weighted average price per share, Beginning balance | $ / shares	$ 3.50
Shares, Granted	100,000
Weighted average price per share, Granted | $ / shares	$ 3.50
Shares, Exercised
Weighted average price per share, Exercised | $ / shares
Shares, Expired	(645,829)
Weighted average price per share, Expired | $ / shares	$ 3.50
Shares, Forfeited
Weighted average price per share, Forfeited | $ / shares
Shares, Ending balance	15,732,940
Weighted average price per share, Ending balance | $ / shares	$ 3.50

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative)		3 Months Ended						9 Months Ended
	Apr. 13, 2023 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) shares	Mar. 31, 2022 USD ($) shares	Sep. 30, 2023 USD ($) Integer $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	May 01, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 30, 2021 shares
Class of Stock [Line Items]
Debt instrument, convertible price per shares | $ / shares								$ 2.50
Debt instrument, convertible, threshold trading days | Integer								5
Number of common stock for services rendered | $		$ 325,301	$ 172,400	$ 1,419,335	$ 167,375	$ 67,800	$ 77,700
Convertible debt issuances value | $			10,017,212	509,033			350,500
Options outstanding, shares		19,153,694						19,153,694			17,586,591
Number of options, exercisable		18,289,721						18,289,721			17,570,591
Extension of warrants for series AA preferred stock | $								$ 3,626,950
Interest expense | $		$ 4,338,759			2,034,021			$ 14,112,098	$ 6,448,771
Fair value of dividends paid in kind | $		$ 150,000	491,634	1,029,939	1,050,475	191,303	472,900
Shares isused for options exercised, shares								117,552
Lender [Member]
Class of Stock [Line Items]
Shares issued, price per share | $ / shares		$ 0.69						$ 0.69
Issued For Services Rendered [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares									190,500
Number of common stock for services rendered | $								$ 1,917,036
Conversion of Debt Extension [Member]
Class of Stock [Line Items]
Convertible debt issuances shares									140,200
Convertible debt issuances value | $									$ 350,500
Stock Issued During Period, Shares, New Issues								203,613
Fair value of dividends paid in kind | $								$ 509,033
Debt Settlement [Member]
Class of Stock [Line Items]
Shares isused for options exercised, shares								117,552
Debt Extension [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								1,346,800
Fair value of dividends paid in kind | $								$ 1,671,573
New Common Stock Issuances [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								60,000
Fair value of dividends paid in kind | $								$ 150,000
Conversion of Preferred to Common Stock [Member]
Class of Stock [Line Items]
Convertible debt issuances shares								1,486,940
Series AA Preferred Stock [Member]
Class of Stock [Line Items]
Fair value of dividends paid in kind | $									$ 1,714,678
Payment in Kind (PIK) Note [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues									1,172,100
Fair value of dividends paid in kind | $									$ 2,196,278
Dividends Paid In Kind [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								142,767
Fair value of dividends paid in kind | $								$ 162,528
Accredited Investor and Consultants [Member]
Class of Stock [Line Items]
Shares of restricted common stock								9,717,035
Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Unvested stock based awards | $		$ 963,322						$ 963,322
Unrecognized compensation, period								2 years 2 months 12 days
Closing stock price | $ / shares		$ 0.20						$ 0.20
Options outstanding and exercisable intrinsic value | $		$ 0						$ 0
2021 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance												3,000,000
Options outstanding, shares		3,420,754						3,420,754
Series BB Restricted Preferred Stock [Member]
Class of Stock [Line Items]
Shares of restricted common stock								953
Series CC Restricted Preferred Stock [Member]
Class of Stock [Line Items]
Shares of restricted common stock								401
Restricted Stock [Member]
Class of Stock [Line Items]
Shares of restricted common stock									3,100,085
Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued		1,000,000						1,000,000
Number of common stock for services rendered | $
Convertible debt issuances shares			401
Convertible debt issuances value | $			$ 4
Extension of warrants for series AA preferred stock | $
Fair value of dividends paid in kind | $
Common Stock [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares		492,500	147,500	990,500	113,500	40,000	37,000
Number of common stock for services rendered | $		$ 4,926	$ 1,475	$ 9,905	$ 1,135	$ 400	$ 370
Convertible debt issuances shares				203,613			140,200
Convertible debt issuances value | $				$ 2,036			$ 1,402
Stock issued during period, value, other								95
Extension of warrants for series AA preferred stock | $
Interest expense | $								$ 3,715,204	$ 634,305
Stock Issued During Period, Shares, New Issues		250,000	528,600	568,200	707,900	106,400	214,500
Fair value of dividends paid in kind | $		$ 2,500	$ 5,286	$ 5,682	$ 7,079	$ 1,064	$ 2,145
Shares isused for options exercised, shares				117,552		25,279
Common Stock [Member] | Issued For Services Rendered [Member]
Class of Stock [Line Items]
Fair value of warrants | $								$ 312,875
Common Stock [Member] | Debt Extension [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues									25,279
Fair value of dividends paid in kind | $									$ 17,433
Common Stock [Member] | New Conversion Debt [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues									368,500
Fair value of dividends paid in kind | $									$ 512,593
Common Stock [Member] | Payment in Kind (PIK) Note [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								170,306
Fair value of dividends paid in kind | $									$ 306,333
Stock Options [Member]
Class of Stock [Line Items]
Options outstanding, shares		3,420,754						3,420,754			1,307,822
Weighted average exercise price | $ / shares		$ 1.23						$ 1.23			$ 0.72
Weighted average remaining term								8 years 1 month 20 days
Number of options, exercisable		2,556,781						2,556,781
Shares isused for options exercised, shares								117,552
Exercisable Options [Member]
Class of Stock [Line Items]
Weighted average remaining term								7 years 9 months
Warrant [Member]
Class of Stock [Line Items]
Number of common stock for services rendered | $
Convertible debt issuances value | $
Options outstanding, shares		15,732,940						15,732,940			16,278,769
Weighted average exercise price | $ / shares		$ 3.50						$ 3.50			$ 3.50
Weighted average remaining term								2 years 5 months 1 day
Class of warrant or right, outstanding	8,897,603
Extension of warrants for series AA preferred stock | $	$ 3,626,950		3,626,950
Fair value of dividends paid in kind | $
Shares isused for options exercised, shares
Issuance warrants, shares		100,000			277,500			100,000	277,500
Strike price, per share | $ / shares		$ 3.50			$ 3.50			$ 3.50	$ 3.50
Fair value of warrants | $								$ 61,609	$ 280,608
Common Stock and Warrant [Member] | Issued For Services Rendered [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares								1,630,500
Common Stock and Warrant [Member] | Conversion of Debt Extension [Member]
Class of Stock [Line Items]
Convertible debt issuances shares								1,258,742
Convertible debt issuances value | $								$ 1,293,270
Common Stock and Warrant [Member] | Payment in Kind (PIK) Note [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								4,094,121
Fair value of dividends paid in kind | $								$ 3,715,204
Series AA Preferred Stock [Member] | Debt Extension [Member]
Class of Stock [Line Items]
Stock issued during period, value, other									4,400
Stock Issued During Period, Shares, New Issues									1,028,800
Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized		1,000,000						1,000,000
Convertible preferred stock, par value | $ / shares		$ 0.01						$ 0.01
Series BB Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized		1,000						1,000		1,000	1,000
Convertible preferred stock, par value | $ / shares		$ 0.01						$ 0.01		$ 0.01	$ 0.01
Preferred Stock, Shares Issued		858						858
Series CC Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, authorized		2,000						2,000		2,000	2,000
Convertible preferred stock, par value | $ / shares		$ 0.01						$ 0.01		$ 0.01	$ 0.01
Preferred Stock, Shares Issued		401						401
Series BB Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, par value | $ / shares		$ 0.01						$ 0.01
Preferred stock voting rights								The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held
Number of shares converted								10,000
Debt instrument, interest rate, stated percentage		300%						300%
Debt instrument, convertible price per shares | $ / shares								$ 2.50
Number of common stock for services rendered, shares								92
Number of common stock for services rendered | $								$ 617,200
Convertible debt issuances shares								741
Convertible debt issuances value | $								$ 2,683,600
Stock issued during period, value, other								62
Series BB Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Stock issued during period, value, other								58
Stock issued during period, value, conversion of units | $								$ 539,487
Series CC Preferred Stock [Member]
Class of Stock [Line Items]
Debt instrument, interest rate, stated percentage		8%						8%
Preferred stock remain outstanding percentage								10%
Preferred stock, dividend rate, percentage								75%
Outstanding shares, precentage		50%						50%
Preferred stock liquidation Preference value | $ / shares		$ 25,000						$ 25,000
Preferred stock, convertible, conversion price | $ / shares		$ 2.50						$ 2.50
Debt instrument, convertible, threshold percentage of stock price trigger								300%
Debt instrument, convertible, threshold trading days | Integer								10
Debt instrument convertible benefically percentage								4.99%
Stock issued during period, shares, other								401
Stock Issued During Period, Value, Other | $								$ 10,017,212

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended						9 Months Ended
	Oct. 18, 2023	Nov. 05, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
common stock, par value			$ 0.01						$ 0.01	$ 0.01
Stock option number of shares granted									2,330,484
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services			492,500	147,500	990,500	113,500	40,000	37,000
Stock Issued During Period, Shares, Conversion of Units									95
Common stock issued for debt extension, shares			250,000	528,600	568,200	707,900	106,400	214,500
Minimum [Member]
Subsequent Event [Line Items]
Debt interest rate			1%						1%
Maximum [Member]
Subsequent Event [Line Items]
Debt interest rate			10%						10%
Subsequent Event [Member]
Subsequent Event [Line Items]
Convertible Debt		$ 439,000
Share Price		$ 2.50
Subsequent Event [Member] | Board of Directors Chairman [Member]
Subsequent Event [Line Items]
Stock option number of shares granted	1,500,000
Numberof stock option exercise price	$ 0.25
Number of years option vested	3 years
Subsequent Event [Member] | Board of Directors Chairman [Member] | Two Thousand Twenty One Equity Plan [Member]
Subsequent Event [Line Items]
Common stock issued for debt extension, shares	300,000
common stock, par value	$ 0.01
Shares of common stock	500,000
Subsequent Event [Member] | Mr Schumacher [Member]
Subsequent Event [Line Items]
Number of option vested percentage	25%
Subsequent Event [Member] | Drs Ting [Member]
Subsequent Event [Line Items]
Number of option vested percentage	25%
Subsequent Event [Member] | Lazarev [Member]
Subsequent Event [Line Items]
Number of option vested percentage	25%
Number of option issuance percentage	25%
Subsequent Event [Member] | Executive Officer [Member]
Subsequent Event [Line Items]
Numberof stock option exercise price	$ 0.25
Subsequent Event [Member] | Series BB Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Other		40
Stock Issued During Period, Shares, Conversion of Units		505,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services		278,500
Stock Issued During Period, Shares, Other		455,350
Stock Issued During Period, Shares, Conversion of Units		145,809
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Debt interest rate		10%
Subsequent Event [Member] | Minimum [Member] | Executive Officer [Member]
Subsequent Event [Line Items]
Numberof stock option exercise price	0.69
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt interest rate		120%
Subsequent Event [Member] | Maximum [Member] | Executive Officer [Member]
Subsequent Event [Line Items]
Numberof stock option exercise price	$ 1.50